THERAPEUTIC MODALITIES Archives - Page 12 of 22

Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library

WuXi AppTec scientists recently contributed to a study which led to the discovery and optimization of a novel series of...

Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase

Tissue transglutaminase (TG2) is a multifunctional enzyme activated in several pathological conditions, including cancer. WuXi AppTec recently contributed to a...

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical...

Emerging Modalities in Drug Discovery

In this webinar, we present the latest advances and challenges facing researchers focused on new and emerging modalities in drug...

Oligonucleotide Therapeutics: Drug Discovery Through Tightly Coupled Chemistry and Biology

Designing effective oligonucleotide therapeutics for clinical applications involves understanding both the chemistry and biology of nucleic acids. In this white...

Oncolytic Virus Platform

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell...

Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)

WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors...

Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors

WuXi AppTec scientists collaborated on a study to characterize a series of pyrroloquinoline derivatives that were designed and synthesized to...

Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research

Learn how parallel medicinal chemistry (PMC) and high-throughput experimentation (HTE) can provide a more focused approach to target molecules, resulting...

Knowledge Library

Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library

Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Emerging Modalities in Drug Discovery

Oligonucleotide Therapeutics: Drug Discovery Through Tightly Coupled Chemistry and Biology

Oncolytic Virus Platform

Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)

Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors

Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research

Contact An Expert Today!

Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library

Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Emerging Modalities in Drug Discovery

Oligonucleotide Therapeutics: Drug Discovery Through Tightly Coupled Chemistry and Biology

Oncolytic Virus Platform

Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)﻿

Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors

Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research

Contact An Expert Today!

Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)